Vir Biotechnology (Vir Biotechnology) FCF Yield % : -60.01 (As of May. 10, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Vir Biotechnology's Trailing 12-Month Free Cash Flow is $-778.97 Mil, and Market Cap is $1,300.72 Mil. Therefore, Vir Biotechnology's FCF Yield % for today is -60.01%.

The historical rank and industry rank for Vir Biotechnology's FCF Yield % or its related term are showing as below:

VIR' s FCF Yield % Range Over the Past 10 Years
Min: -72.43 Med: -3.06 Max: 60.23
Current: -60.01

During the past 7 years, the highest FCF Yield % of Vir Biotechnology was 60.23%. The lowest was -72.43%. And the median was -3.06%.

VIR's FCF Yield % is ranked worse than
77.7% of 1556 companies
in the Biotechnology industry
Industry Median: -14.085 vs VIR: -60.01

Vir Biotechnology's FCF Margin % for the quarter that ended in Mar. 2024 was -217.29%.

Vir Biotechnology FCF Yield % Historical Data

The historical data trend for Vir Biotechnology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology FCF Yield % Chart

Vir Biotechnology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-10.23

-5.79

-1.26

47.31

-59.03

Vir Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-17.02	-48.44	-50.64	-32.29	-32.34

Competitive Comparison of Vir Biotechnology's FCF Yield %

For the Biotechnology subindustry, Vir Biotechnology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vir Biotechnology's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's FCF Yield % falls into.

Vir Biotechnology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Vir Biotechnology's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-800.358	/	1355.89686
	=	-59.03%

Vir Biotechnology's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-111.262	*	4	/	1376.09972
	=	-32.34%

Vir Biotechnology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Vir Biotechnology FCF Yield % Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vir Biotechnology (Vir Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158

Website

https://www.vir.bio

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Executives

Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang	officer: Chief Medical Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice	officer: Chief Administrative Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De	officer: Chief Executive Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly	officer: Chief Technology Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee	officer: Chief Financial Officer	7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer	officer: Chief Business Officer, Global	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos	director, officer: President and CEO	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn	officer: CFO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin	officer: EVP, Research & CSO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano	director	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001